Talecris Biotherapeutics
United States

  Home About Talecris US Our Products Our Services Media Center Careers  
Our Products
Gamunex®
Prolastin®
Koāte®-DVI
Hypermunes™
GamaSTAN™ S/D
Dosing
HyperHEP B™ S/D
Dosing
HyperRAB™ S/D
Dosing
HyperRHO™ S/D
Dosing
HyperTET™ S/D
Dosing
Ultrasafe® Needle Guard
Distributors
Plasbumin®/Plasmanate®
Thrombate III®

HyperRHO™ S/D, Rh0 (D) Immune Globulin (Human) Dosing


Indication
Dosage
Postpartum prophylaxis—preferably within 72 hours of delivery
If volume of red blood cells that has entered the circulation ≤15 mL
1500 IU
If large (>30 mL whole blood or 15 mL red blood cells) fetomaternal hemorrhage is suspected
Fetal red cell count should be performed to determine dosage (See complete prescribing information [PDF])
Antenatal prophylaxis
At approximately 28 weeks gestation
1500 IU
Postpartum, preferably within 72 hours of delivery if infant is Rh positive
1500 IU
Following threatened abortion
1500 IU
Following miscarriage, abortion, or termination of ectopic pregnancy
If pregnancy terminated prior to 13 weeks gestation
250 IU (HyperRHO®) Mini-Dose
If pregnancy terminated at or beyond 13 weeks gestation
1500 IU
Following amniocentesis at 15-18 weeks gestation or during third trimester
1500 IU
Following abdominal trauma in second or third trimester*†
1500 IU
Transfusion
For dosage calculation (See complete prescribing information [PDF])


*If >15 mL of red cells is suspected due to fetomaternal hemorrhage, see postpartum prophylaxis above.
†If abdominal trauma, amniocentesis, or other adverse event required administration of HyperRho-D® at 13-18 weeks gestation, another 1500 IU dose should be given at 26-28 weeks gestation.

Product Information
Product
NDC#
Description
Size
HyperRHO™ S/D (Full Dose)
13533-631-02
Single Dose Syringe (safety syringe)
1500 IU
HyperRHO™ S/D (Mini-Dose)
13533-631-06
Single Dose Syringe (10 pack) (safety syringe)
250 IU

 

 

Print This Page
E-mail This Page
Talecris Biotherapeutics
Contact Talecris    Glossary    Site Map
General Conditions of Use    Privacy Statement    California Compliance
© 2008 Talecris Biotherapeutics